Labcorp Holdings Inc. (LH) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with increased revenue guidance across segments, margin improvements, and raised EPS guidance. The Q&A section reveals organic demand growth and strategic initiatives to offset potential risks like PAMA. Despite some uncertainties, the overall sentiment is positive, with raised guidance, margin expansion, and strong segment performance. The lack of specific guidance on some issues is outweighed by the positive financial outlook and strategic growth plans.
Key Financial Performance
Enterprise Revenue $3.6 billion, representing 9% growth compared to last year. The increase was driven by organic growth of 6.2%, acquisitions contributing 1.7%, and foreign currency translation of 0.7%.
Margin Improved by 100 basis points, driven by Diagnostics.
Adjusted EPS $4.18, up 19% from last year. The increase was driven by strong revenue growth and margin improvement.
Free Cash Flow $281 million, compared to $162 million last year, an increase of $119 million primarily driven by higher cash earnings.
Diagnostics Revenue $2.8 billion, an increase of 8.5% compared to last year. Organic growth contributed 6.3%, acquisitions 2.2%, and price/mix increased 3.7%.
Diagnostics Margin 16.3% of revenue, up 110 basis points from last year, driven by organic demand and strong performance of Invitae.
Biopharma Laboratory Services (BLS) Revenue $799 million, an increase of 8.3% compared to last year. Organic revenue grew 5.3%, and foreign currency translation contributed 3%.
BLS Margin 16.5% of revenue, up from 16.4% last year, driven by organic demand.
Adjusted Operating Income $513 million or 14.4% of revenue, compared to $441 million or 13.4% of revenue last year. The increase was driven by organic demand and strong performance of Invitae.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Innovative Testing Capabilities: Introduced several new tests, including expanded oncology and genetic testing portfolio, OmniSeq INSIGHT for ovarian tumors, PGDx elio tissue complete for pan solid tumors, and FDA-approved at-home colorectal cancer screening test.
Neurology Testing: Launched the first FDA-cleared blood-based test for Alzheimer's diagnosis in specialty care settings and planning to offer another test for primary care in early 2026.
Consumer-Initiated Tests: Launched tests for lead exposure, ApoB for heart health, and a healthy aging panel through Labcorp OnDemand.
Acquisitions and Partnerships: Signed agreements to acquire clinical laboratory assets from Empire City Laboratories and Laboratory Alliance of Central New York, and manage inpatient labs for Crouse Health. Completed acquisition of oncology and clinical testing assets from BioReference Health.
Expansion in High-Growth Areas: Focused on oncology, women's health, neurology, and autoimmune diseases, leveraging genetic testing and innovation to drive growth.
AI and Digital Investments: Launched Labcorp Test Finder, an AI tool for test selection, and collaborated with Roche to digitalize pathology workflows. Deployed AI platforms for cytology and microbiology to improve turnaround times.
LaunchPad Initiative: Continued progress on cost-saving measures, offsetting personnel cost increases.
Restructuring in Early Development: Divesting or restructuring $50 million in annual revenue from noncore areas to streamline operations and improve income.
Focus on Strategic Relationships: Strengthened partnerships with health systems and regional laboratories to expand patient and provider networks and improve efficiencies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Early Development Revenue: Lower-than-expected revenue due to delayed study starts. In response, the company is beginning to divest or restructure through site consolidation, impacting approximately $50 million in annual revenue in noncore areas.
Currency Impact: Unfavorable impact of currency fluctuations, leading to a 40 basis point reduction in the midpoint of Biopharma Laboratory Services (BLS) revenue guidance.
Acquisition Timing: Timing of acquisition revenue has led to a 40 basis point reduction in the midpoint of enterprise revenue growth guidance.
Economic and Market Conditions: Forward-looking statements indicate potential risks from global economic and market conditions, which could impact operating and financial results, cash flows, and financial condition.
Regulatory and Compliance Risks: Potential risks associated with maintaining compliance with regulatory requirements, especially in light of new product launches and acquisitions.
Operational Efficiency: Challenges in maintaining operational efficiency while integrating acquisitions and expanding into high-growth specialty areas.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Full Year Revenue Growth: Updated guidance range to 7.4% to 8%, with a lowered midpoint by 40 basis points due to timing of acquisition revenue and unfavorable currency impact.
Diagnostics Segment Revenue Growth: Maintained midpoint versus prior guidance, narrowed growth range to 7.2% to 7.8%, assuming approximately 4.5% organic revenue growth.
Biopharma Laboratory Services (BLS) Revenue Growth: Expected growth of 5.7% to 7.1% versus prior year, with a lowered midpoint by 40 basis points due to unfavorable currency impact. Central Labs expected to grow mid-single digits, while Early Development expected to grow low single digits for the full year.
Adjusted EPS Guidance: Range updated to $16.15 to $16.50, with an implied growth rate at the midpoint of 12%. Range narrowed and midpoint raised by approximately $0.05.
Free Cash Flow Guidance: Range updated to $1.165 billion to $1.285 billion, with the midpoint raised by $25 million due to strong cash flow generation year-to-date.
Capital Expenditures: Expected to be approximately 3.5% of revenue for the full year.
Early Development Revenue: Expected to grow low single digits for the full year, with Q4 presenting the most challenging year-over-year comparison.
Central Labs Revenue: Expected to grow mid-single digits for the full year.
Enterprise Margins: Expected to increase with improvements in both Diagnostics and BLS segments in 2025 versus 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends paid: $60 million in dividends were paid during the quarter.
Share repurchase: $25 million worth of stock was repurchased during the quarter.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you seeing an increase in utilization from the exchange population due to potential benefit loss or cost increase in 2026?
A:Adam Schechter explained that the uptick in utilization is more due to organic volume increases, demographics, and market share gains rather than concerns about losing ACA benefits. Doctors' appointment availability limits the impact of such concerns.
Q:Can you break down the 40 basis points between currency and acquisitions?
A:Adam Schechter stated that $13 million was from foreign exchange, and the rest was from acquisitions, which were timing-related. Some acquisitions closed later than anticipated, impacting the timeline.
Q:How much of the organic price/mix growth is proactive versus reactive?
A:Adam Schechter and Julia Wang explained that organic price/mix grew 2.8%, driven by test mix and Invitae. Unit price remained flat, and mix growth was supported by partnerships, aging population, and specialty testing. Invitae's impact was more pronounced in Q3 but will moderate in Q4.
Q:What factors led to the site consolidation in the Early Development business, and what is the earnings impact?
A:Adam Schechter explained that site consolidation was due to delays in study starts despite stable RFPs and win rates. The consolidation will reduce $50 million in annualized revenue but slightly increase operating income.
Q:What are the expectations and mitigation efforts for PAMA's impact?
A:Adam Schechter stated that PAMA could have a $100 million impact on top and bottom lines in 2026. They are advocating for the RESULTS Act and planning to offset $25 million of the impact through AI and efficiency initiatives.
Q:What is the contribution and growth rate of consumer-driven testing?
A:Adam Schechter noted significant growth in consumer-driven testing but stated it hasn't reached critical mass for separate reporting. They are adding new tests and leveraging platforms like the Ovia app to engage consumers.
Q:Can you elaborate on the Diagnostics segment margin expansion and future expectations?
A:Julia Wang explained that Diagnostics margin improved by 110 basis points in Q3 due to organic demand, Invitae, and LaunchPad savings. Margins are expected to moderate in Q4 due to seasonality but show full-year expansion.
Q:Why does the 2025 EPS guidance have a wide range?
A:Adam Schechter explained that the range is due to uncertainties in timing related to divestitures and site consolidations in the Biopharma Laboratory Services segment.
Q:Can you meet your long-range plan (LRP) if PAMA comes back?
A:Adam Schechter stated it is too early to provide specifics for 2026 but emphasized efforts to offset PAMA's impact through LaunchPad and AI initiatives.
Q:Has the hospital M&A pipeline reaccelerated, and has your deal criteria changed?
A:Adam Schechter confirmed a strong hospital M&A pipeline. Deal criteria remain focused on return on cost of capital, with hospital lab management typically neutral to margins when combined with reference and outreach work.
Q:How are you prioritizing R&D investments in esoteric tests, and what is the strategy for Geneoscopy's ColoSense?
A:Adam Schechter emphasized focus on oncology, women's health, neurology, and autoimmune areas. They are agnostic to developing tests internally or acquiring/licensing them. No specific updates on ColoSense commercialization or reimbursement were provided.
Q:Can you provide more color on bookings between Central Lab and Early Development?
A:Adam Schechter noted a book-to-bill ratio of 0.9 for Q3, with Central Lab showing strong bookings and Early Development facing delays in study starts despite stable RFPs and win rates.
Q:What are the expected revenue and EPS accretion from acquisitions for 2025 and 2026?
A:Adam Schechter stated that acquisitions typically contribute 1.5% to 2.5% growth annually. Specific operating income or margin details for individual deals were not provided.
Q:What is driving the Central Lab strength, and what is its durability?
A:Adam Schechter highlighted 10% growth in Central Lab revenue (7% constant currency) and expects mid-single-digit growth for the full year. Strong book-to-bill and large multi-year studies contribute to its durability.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the commercialization strategy and reimbursement updates for Geneoscopy's ColoSense. Additionally, they did not provide specific operating income or margin details for acquisitions, citing general growth expectations instead.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI automation
AI capability
AI others
Alzheimer
Central
Diagnostic
Epic
Julia
Labcorp
Margin basis
New York
access test
area science
blood test
care setting
cytology
experience efficiency
microbiology
momentum
neurology
pathology
patient provider
position
profiling test
result outlook
science technology
specialty
technology customer
test menu
therapy selection
tissue
tumor
turnaround time
use measure
workflow
LH Transcript
Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary indicates solid financial performance with projected revenue growth across segments, margin expansion, and double-digit EPS growth. The Q&A section reveals positive sentiment towards strategic initiatives like the CRUSH initiative, LaunchPad, and Labcorp OnDemand. Despite some uncertainties, such as reimbursement for esoteric tests, the overall outlook remains optimistic. The strong book-to-bill ratio and robust deal pipeline further support a positive sentiment. Without market cap data, the prediction leans towards a 'Positive' outlook, expecting a 2% to 8% stock price increase over the next two weeks.
Labcorp Holdings Inc. (LH) Q4 2025 Earnings Call Transcript
Unknown2-17
The earnings call reveals mixed sentiments. While revenue growth and EPS guidance are positive, there are concerns about unfavorable currency impacts, conservative guidance, and risks in 2026. The Q&A section highlights some uncertainties and management's avoidance of specific details, which tempers optimism. The absence of a market cap limits the ability to predict strong movements, leading to a neutral sentiment.
Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
LH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
